Targeting the dipeptidyl peptidase activity with low molecular weight enzyme inhibitors restores incretin activity and has led to the successful development of a DPP-IV inhibitor, sitagliptin, as an effective therapy for Type 2 diabetes [3]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.